ArticleJournal of clinical medicine2022
Marginal versus Standard Donors in Heart Transplantation: Proper Selection Means Heart Transplant Benefit.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Use of extended criteria donor cardiac allografts after multiple offers is associated with inferior post-transplant outcomes.JHLT open · 2026Article
- Extended Criteria Donor Use in Heart Transplantation: A Promising Strategy to Expand the Donor Pool.Journal of clinical medicine · 2026Article
- Orthotopic Heart Transplantation with Concurrent Coronary Artery Bypass Grafting Using In Situ Internal Thoracic Artery.Journal of cardiovascular development and disease · 2026Article
- Optimizing recovery of marginal donor hearts with low ejection fraction: A national retrospective study from Switzerland.JHLT open · 2026Article
- Heart Transplantation from Donors with Takotsubo Cardiomyopathy: Clinical Outcomes and Early Experience from a Single Center.Journal of clinical medicine · 2026Article
- Article
- Optimizing Temperature in Ex Situ Heart Perfusion: A Comparative Review of Traditional and Novel Methods in Heart Transplantation.Journal of cardiovascular development and disease · 2026Review
- Kinetics of Procalcitonin, CRP, IL-6, and Presepsin in Heart Transplant Patients Undergoing Induction with Thymoglobulin (rATG).Journal of clinical medicine · 2025Article
- Normothermic regional perfusion and donation after circulatory death heart-lung procurement.Annals of cardiothoracic surgery · 2025Article
- Heart transplantation from donation after circulatory death: a meta-analysis of national registries.Annals of cardiothoracic surgery · 2024Article
- Successful Resuscitation of Porcine Hearts After 12 and 24 h of Static Cold Storage With Normothermic Ex Situ Perfusion.Transplantation direct · 2024Article
- Examining a 12-year experience within Kazakhstan's national heart transplantation program.Scientific reports · 2024Article
- Article
- Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Support in New Era of Heart Transplant.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Tacrolimus and Cyclosporin Pharmacotherapy, Detection Methods, Cytochrome P450 Enzymes after Heart Transplantation.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- ADONHERS (Aged DONor HEart Rescue by Stress Echo) National Protocol: Recipient's Survival after 10-Year Follow-Up.Journal of clinical medicine · 2023Article
- The Clinical Outcomes of Marginal Donor Hearts: A Single Center Experience.Korean circulation journal · 2023Article
- To Take or Not to Take: The Dilemma With Marginal Donor Heart?Korean circulation journal · 2023Article
- Thoracic organ machine perfusion: A review of concepts with a focus on reconditioning therapies.Frontiers in transplantation · 2023Review
- A Device Strategy-Matched Comparison Analysis among Different Intermacs Profiles: A Single Center Experience.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we assessed the mid-term outcomes of patients who received a heart donation from a marginal donor (MD), and compared them with those who received an organ from a standard donor (SD).
methodsAll patients who underwent HTx between January 2012 and December 2020 were enrolled at a single institution. The primary endpoints were early and long-term survival of MD recipients. Risk factors for primary graft failure (PGF) and mortality in MD recipients were also analyzed. The secondary endpoint was the comparison of survival of MD versus SD recipients.
resultsIn total, 238 patients underwent HTx, 64 (26.9%) of whom received an organ from an MD. Hospital mortality in the MD recipient cohort was 23%, with an estimated 1 and 5-year survival of 70% (59.2-82.7) and 68.1% (57.1-81), respectively. A multivariate analysis in MD recipients showed that decreased renal function and increased inotropic support of recipients were associated with higher mortality (
conclusionsSelected MDs are a valuable resource for expanding the cardiac donor pool, showing promising results. The use of MDs after prolonged ischemic times, increased inotropic support of the MD or the recipient and decreased renal function are associated with worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.